Dimitriou et al. recently reported a European multicenter experience of 125 patients with advanced melanoma with and without brain metastases treated either with anti-PD-1 monotherapy (97 patients) or combined with anti-CTLA-4 (28 patients) [21]. This evidence concerns the gene CTLA4 and melanoma.